Market revenue in 2021 | USD 81.7 million |
Market revenue in 2028 | USD 154.0 million |
Growth rate | 9.5% (CAGR from 2021 to 2028) |
Largest segment | Attr-cm |
Fastest growing segment | ATTR-PN |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | ATTR-PN, ATTR-CM |
Key market players worldwide | Pfizer Inc, Johnson & Johnson, Ionis Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, BridgeBio Pharma Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Astellas Pharma Inc, Prothena Corp PLC, Acrotech BioPharma, SOM Biotech |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to transthyretin amyloidosis treatment market will help companies and investors design strategic landscapes.
Attr-cm was the largest segment with a revenue share of 72.09% in 2021. Horizon Databook has segmented the Italy transthyretin amyloidosis treatment market based on attr-pn, attr-cm covering the revenue growth of each sub-segment from 2018 to 2028.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy transthyretin amyloidosis treatment market , including forecasts for subscribers. This country databook contains high-level insights into Italy transthyretin amyloidosis treatment market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account